NRX Pharmaceuticals, Inc. (NRXP) Stock Price & How to Invest

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company targeting central nervous system and psychiatric conditions, with an emphasis on the NMDA receptor pathway. Its lead assets are NRX-100, a preservative-free intravenous ketamine that has received Fast Track designation for suicidal ideation in depression including bipolar depression, and NRX-101, an oral D-cycloserine and lurasidone combination that has received Breakthrough Therapy designation for suicidal bipolar depression and is also being explored as an adjunct to transcranial magnetic stimulation. The company has pursued an ANDA pathway for its preservative-free ketamine (marketed under the KETAFREE name), with an FDA decision anticipated in 2026.

Beyond the drug pipeline, NRx has built HOPE Therapeutics, a subsidiary intended to operate as an interventional-psychiatry care-delivery organization. HOPE opened and acquired clinics, largely in Florida, offering treatments such as ketamine, TMS, and related neuroplastic approaches combined with physician-led care, and it began generating early clinical revenue. Management has described plans to spin out a portion of HOPE to NRx shareholders and potentially list it separately, a structure that added complexity and was the subject of an arbitration process.

As of the first half of 2026, NRx remained a small, cash-constrained company reporting net losses and a modest cash balance, supplemented by at-the-market and other financings and an effective shelf registration that allows further capital raises. The investment case is highly catalyst-driven: an FDA decision on preservative-free ketamine, progress on NRX-101, and execution of the HOPE clinic and spin-out strategy. Each of these can move the stock sharply in either direction, and the company's ability to fund itself without heavy dilution is a recurring question.

NRXP is a speculative, cash-constrained clinical-stage biotech with minimal product revenue and a history of net losses. Its reported cash balance has been small relative to its needs, so it relies on at-the-market sales, other financings, and an effective shelf registration, all of which point to ongoing dilution risk for existing shareholders. The investment case is binary and catalyst-dependent: FDA decisions on preservative-free ketamine, clinical outcomes for NRX-101, and execution of the HOPE clinic and spin-out plan can each fail or slip. Regulatory rejection, trial disappointment, manufacturing or commercialization setbacks, litigation or arbitration outcomes, and difficulty raising capital on acceptable terms are all real hazards. The stock can be highly volatile and, like many micro-cap biotechs, carries a meaningful risk of permanent capital loss.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NRX Pharmaceuticals, Inc.'s investor relations page or your broker.

• Revenue: Product revenue is minimal; the HOPE Therapeutics clinics began generating early clinical revenue, but the company is pre-commercial on its drug pipeline.
• Profitability: NRx reports recurring net losses as a clinical-stage company; profitability is not expected until and unless products reach the market at scale.
• Cash runway: The cash balance has been small relative to spending, supplemented by ATM and other financings; runway is limited and a frequent focus for investors.
• Financing / dilution: An effective shelf registration and at-the-market program give flexibility to raise capital quickly, which also means ongoing dilution risk for shareholders.
• Pipeline: Value is concentrated in NRX-100 (preservative-free ketamine, with a 2026 FDA decision anticipated) and NRX-101, plus the HOPE clinic network and potential spin-out.
• Valuation: As a pre-revenue, catalyst-driven biotech, valuation reflects the market's probability-weighted view of regulatory and clinical outcomes rather than current earnings.

All figures here are approximate and qualitative. A clinical-stage biotech's cash position, share count, pipeline status, and regulatory timelines change frequently, sometimes on short notice. Verify the latest numbers from NRx filings, its investor relations releases, and a live quote before making any decision.

There are three common ways to get NRXP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NRXP sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where NRXP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

NRXP is a speculative clinical-stage CNS biotech built around ketamine and NRX-101 for suicidal depression plus the HOPE Therapeutics clinic network. The bull case is near-term FDA catalysts and a spin-out unlocking value. The bear case is a tiny cash balance, ongoing dilution, and binary trial and regulatory risk.